Read J L, Lee K B
Health Aff (Millwood). 1994 Summer;13(3):215-25. doi: 10.1377/hlthaff.13.3.215.
Funding for biomedical research has shifted from government to the private sector. One reason is rapid expansion in the number and strength of U.S. biotechnology companies, which collectively spend more than $6 billion a year on biomedical research. Most of these companies are not yet profitable and therefore depend on flows of capital from private investors, Wall Street, and large pharmaceutical company collaborations. Investment in the new drugs, devices, and vaccines in this pipeline is sensitive to signals emanating from the debate on health care reform, suggesting that new federal policy will have a major impact on steering the type of innovation to emerge in the future.
生物医学研究的资金来源已从政府转向了私营部门。原因之一是美国生物技术公司的数量和实力迅速增长，这些公司每年在生物医学研究上的总支出超过60亿美元。这些公司大多尚未盈利，因此依赖私人投资者、华尔街以及与大型制药公司合作的资金流。对这条渠道中的新药、设备和疫苗的投资对医疗保健改革辩论发出的信号很敏感，这表明新的联邦政策将对引导未来出现的创新类型产生重大影响。
